Search companies

Live

PROTEOMICS INTERNATIONAL LABORATORIES LTD (ASX: PIQ)

Health care · News and insights

Price unavailable

Latest PIQ announcements

Announcement Insights

Proteomics International Begins National Test Rollout, Seeks Up To $5 Million For Expansion

Proteomics International has moved Promarker D and Promarker Eso from controlled release to national distribution through Healius, while seeking up to $5 million to support the commercial push. The share plan is intended to fund product launches, clinical and reimbursement work, laboratory capacity and US preparations, and is expected to support operations to October 2027; Promarker Endo is targeted for commercial availability in FY27 Q3, subject to clinical deployment and applicable requirements. Quarter-end cash was approximately $2 million, rising to a pro forma approximately $4 million after a research and development tax incentive.

Updated 11 Nov 2026, 09:13 AM Sydney time
Share
SourcesChange of Director's Interest NoticeSecurity Purchase Plan Offer Booklet UpdateAmended Notice of Annual General Meeting/Proxy FormShare Purchase Plan Cleansing NoticeSecurity Purchase Plan Offer BookletInvestor Webinar PresentationProteomics International Launches Share Purchase PlanProposed issue of securities - PIQQuarterly Activities/Appendix 4C Cash Flow Report
Comments

Proteomics Director Buys Shares As Company Seeks Up To $5 Million

2026-11-11 · Health care

PIQ: $0.096 -1.03% · MC: $16M

Proteomics International director James Williams bought 120,000 shares on market at an average of 10 cents each, taking his indirect holding to that amount. The purchase follows the company’s recently announced share purchase plan, which aims to raise up to $5 million; the plan’s shares are offered at 10 cents each, with attaching options subject to shareholder approval.

Updated 2026-11-11 08:59
Share
SourcesChange of Director's Interest Notice
Comments

Proteomics International Updates Share Plan Booklet as $5 Million Raise Continues

2026-11-06 · Health care

PIQ: $0.098 -2.00% · MC: $16M

Proteomics International updated its share purchase plan booklet to correct contact details and website and registry links; the changes do not alter the offer’s terms. The plan is intended to raise up to $5 million to support product launches, clinical and reimbursement work, laboratory capacity and US market preparations, with free attaching options subject to shareholder approval.

Updated 2026-11-06 12:06
Share
SourcesSecurity Purchase Plan Offer Booklet Update
Comments

Proteomics Adds Three SPP Option Votes To Amended AGM Agenda

2026-11-05 · Health care

PIQ: $0.100 +2.04% · MC: $16M

Proteomics International Laboratories has added three resolutions to its November AGM agenda, seeking approval to issue up to 50 million free options to unrelated share purchase plan participants and up to 300,000 each to directors Aaron Brinkworth and Paul House. Shareholders who want to vote on the new resolutions must use the replacement proxy form; previously lodged forms remain valid for the original resolutions unless replaced.

Updated 2026-11-05 16:43
Share
SourcesAmended Notice of Annual General Meeting/Proxy Form
Comments

Proteomics International Opens Up to $5 Million Share Purchase Plan

2026-11-04 · Health care

PIQ: $0.098 +3.16% · MC: $16M

Proteomics International Laboratories has opened the share purchase plan announced earlier this week, seeking up to $5 million before costs, with discretion to accept oversubscriptions. The target is equivalent to roughly a quarter of its recently observed $20 million market capitalisation. Eligible shareholders can subscribe at $0.10 per share and receive a free option for each share, subject to shareholder approval. The company says the proposed raise is expected to support operations until October 2027 and fund commercialisation, including the planned PromarkerEndo launch and US market preparations.

Updated 2026-11-04 13:04
Share
SourcesShare Purchase Plan Cleansing NoticeSecurity Purchase Plan Offer BookletInvestor Webinar Presentation
Comments

Proteomics International Seeks Up to $5 Million in Discounted Share Plan

2026-11-02 · Health care

PIQ: $0.091 -24.17% · MC: $16M

Proteomics International Laboratories is seeking up to $5 million before costs through a share purchase plan, equivalent to about a quarter of its recent market capitalisation. The offer price is $0.10 per share, a discount of approximately 17% to the previous closing price, with a free option for each share subject to shareholder approval. The proposed funding is intended to support commercialisation, clinical and reimbursement work, product launches and US market preparations. The company recently began the national rollout of its Promarker D and Promarker Eso tests through Healius.

Updated 2026-11-02 10:26
Share
SourcesProteomics International Launches Share Purchase PlanProposed issue of securities - PIQ
Comments

Proteomics International Begins National Rollout Of Promarker Tests Through Healius

2026-10-30 · Health care

PIQ: $0.120 +2.13% · MC: $16M

Proteomics International has begun a national rollout of Promarker D and Promarker Eso through Healius, following their controlled release in Western Australia and the Northern Territory. It reported quarterly operating cash outflows of approximately $2 million and cash of approximately $2 million at quarter-end; a subsequent approximately $2 million research and development tax incentive lifted its pro forma cash position to approximately $4 million. Promarker Endo is expected to become commercially available in FY27 Q3, subject to clinical deployment and applicable requirements.

Updated 2026-10-30 17:05
Share
SourcesQuarterly Activities/Appendix 4C Cash Flow Report
Comments